Realidades y retos del aborto con medicamentos en México. Georgina Sánchez Ramírez

AO, Akinyemi AI, Berry AL, Erinfolami TP, Olagunju OS, Väisänen H, Bankole A, 2020, “Women’s self-reported experiences using misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria” en BMJ Open, Vol. 10, núm. 5, p. e034670.

      Suh S, 2014, “Rewriting abortion: deploying medical records in jurisdictional negotiation over a forbidden practice in Senegal” en Soc Sci Med, Vol. 108, pp. 20–33.

      Vázquez-Quesada L, Shukla A, Vieitez I , Acharya R, RamaRao S, 2020, “Abortion Self-Care: A Forward-Looking Solution To Inequitable Access” en Int Perspect Sex Reprod Health, Vol. 46, Suppl 1, pp. 91-95.

      Viggiano M, Faúndes A, Borges AL, y otros, 1996, “Disponibilidade de misoprostol e complicacoes de aborto provocado em Goiaˆnia” en J Bras Ginecol, Vol. 106, pp. 55–61.

      Walt RP, 1992, “Misoprostol for the treatment of peptic ulcer and anti-inflammatory drug induced gastroduodenal ulceration” en N Engl J Med, Vol. 327, pp. 1575–80.

      WHO, 2012, Safe abortion: technical and policy guidance for health systems, Ginebra.

      Zamanian M, Reza Baneshi M, Haghdoost A , Zolala F, 2016, “Estimating the visibility rate of abortion: a case study of Kerman, Iran” en BMJ Open, Vol. 6, núm. 10, p e012761.